targeted drug-associated moderated and severe rash
Conditions
Interventions
test group:zhiyang pingfu decoction + standard treatment
control group:placebo + standard treatment
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) the patients with malignant tumor were confirmed by pathology; 2) taking EGFRIs preparations and have EGFRIs-related rash; 3) Aged over 18 years old, the KPS is more than 60 points,and the expected survival is more than 3 months; 4) the rash classification is grade 2(moderate) or above according to the MASCC, and the symptom lasts for more than one day; 5) no intelligence and mental disorders, normal language expression ability,and can cooperate to evaluate symptoms and quality of life; 6) patients signed the informed consent.
Exclusion criteria
Exclusion criteria: 1) Epidermal growth factor inhibitors (EGFRIs) have been stopped; 2) no rash or rash was found in patients with MASCC grade 1 (mild); 3) with other skin diseases at the same time; 4) with other serious complications, such as severe heart, liver or kidney failure; 5) allergic constitution; 6) poor compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rash classification;Inflammatory factors;Pruritus factors; | — |
Secondary
| Measure | Time frame |
|---|---|
| Diameter of bacteriostasis circle;Quality of life;the dosage of EGFRIs; | — |
Countries
China
Contacts
Public ContactHuijuan Cui
China-Japan Friendship Hospital
Outcome results
None listed